Program
Multiple-ascending Doses (MAD) study
Its studies are mostly in Obesity, led by Chengdu Zenitar Biomedical Technology.
Furthest: phase 1, since Nov 12, 20261 company-led study, 1 open or runningNext primary completion: Sep 30, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Chengdu Zenitar Biomedical Technology | 11 open or running | phase 1since Nov 12, 2026 | Nov 12, 2026 | Sep 30, 2027phase 1 · NCT07946783 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 12, 2026First study: phase 1 study in Obesity With Cardiovascular Risk StudyFirst studyNCT07946783 · 103 planned · Australia
Ahead
- Sep 30, 2027Primary completion: phase 1 study in Obesity With Cardiovascular Risk StudyNCT07946783
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07946783Obesity With Cardiovascular Risk Study · Australia | 1 | Not yet recruiting | Sep 30, 2027 | 103 |
How it is read
Names in the registry
- “Multiple-ascending Doses (MAD) study”, 1 entry
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.